 when the in-person requirement had not been enforced. And that relates back to that temporary COVID change that I referenced earlier. But the agency's official position is that that data by itself is not an indicator of the safety profile of the drug. And the FDA even cautions that the number of suspected reactions in the system should not be used to determine the likelihood of a side effect occurring.